The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some questions consumers have.

A report published in November by KFF, a health information nonprofit that includes KFF Health News, found only 13 states ...

Should Medicare and Medicaid eventually cover new weight loss drugs such as Ozempic and Wegovy? This week, Audacy took a look ...

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

Millions of Americans fighting obesity faced a setback last month when the Trump administration declined to allow Medicare and Medicaid to cover popular weight loss drugs like Wegovy and Zepbound.

Patients taking Eli Lilly’s drug to combat obesity, Zepbound, lost more weight than those who took Novo Nordisk’s Wegovy in a ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Trump administration has rejected Biden proposal to expand coverage Medicare currently covers Ozempic, Mounjaro solely for diabetes Wegovy, Zepbound not covered for weight loss Trump ...

The Trump administration announced it will not finalize a rule proposed by the Biden administration that would have allowed ...